Literature DB >> 21371048

The pharmaceuticalisation of society? A framework for analysis.

Simon J Williams1, Paul Martin, Jonathan Gabe.   

Abstract

Drawing on insights from both medical sociology and science and technology studies this article provides a critical analysis of the nature and status of pharmaceuticalisation in terms of the following key dimensions and dynamics: (i) the redefinition or reconfiguration of health 'problems' as having a pharmaceutical solution; (ii) changing forms of governance; (iii) mediation; (iv) the creation of new techno-social identities and the mobilisation of patient or consumer groups around drugs; (v) the use of drugs for non-medical purposes and the creation of new consumer markets; and, finally, (vi) drug innovation and the colonisation of health futures. Pharmaceuticalisation, we argue, is therefore best viewed in terms of a number of heterogeneous socio-technical processes that operate at multiple macro-levels and micro-levels that are often only partial or incomplete. The article concludes by drawing out some broader conceptual and reflexive issues this raises as to how we might best understand pharmaceuticalisation, based on our analysis, as a framework for future sociological work in this field.
© 2011 The Authors. Sociology of Health & Illness © 2011 Foundation for the Sociology of Health & Illness/Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21371048     DOI: 10.1111/j.1467-9566.2011.01320.x

Source DB:  PubMed          Journal:  Sociol Health Illn        ISSN: 0141-9889


  27 in total

1.  The Pharmaceuticalization of the Tobacco Industry.

Authors:  Yogi Hale Hendlin; Jesse Elias; Pamela M Ling
Journal:  Ann Intern Med       Date:  2017-07-18       Impact factor: 25.391

2.  Peering into the pharmaceutical "pipeline": investigational drugs, clinical trials, and industry priorities.

Authors:  Jill A Fisher; Marci D Cottingham; Corey A Kalbaugh
Journal:  Soc Sci Med       Date:  2014-08-19       Impact factor: 4.634

3.  Personalised medicine, disease prevention, and the inverse care law: more harm than benefit?

Authors:  Jack E James
Journal:  Eur J Epidemiol       Date:  2014-04-12       Impact factor: 8.082

4.  Low-Risk Cannabis Use Is an Oxymoron.

Authors:  Alain Braillon
Journal:  Am J Public Health       Date:  2017-12       Impact factor: 9.308

5.  Neurobiological narratives: experiences of mood disorder through the lens of neuroimaging.

Authors:  Daniel Z Buchman; Emily L Borgelt; Louise Whiteley; Judy Illes
Journal:  Sociol Health Illn       Date:  2012-05-03

6.  Drivers of medicalization in the Canadian Adult Obesity Clinical Practice Guidelines.

Authors:  Andrea E Bombak; Louise Adams; Patricia Thille
Journal:  Can J Public Health       Date:  2022-07-15

7.  Research in haematological cancers: What do patients in the Netherlands prioritise?

Authors:  Anne-Floor M Schölvinck; Bert M B de Graaff; Mechteld J van den Beld; Jacqueline E W Broerse
Journal:  Eur J Cancer Care (Engl)       Date:  2019-01-23       Impact factor: 2.328

Review 8.  Drugs, cancer and end-of-life care: a case study of pharmaceuticalization?

Authors:  Courtney Davis
Journal:  Soc Sci Med       Date:  2014-12-02       Impact factor: 4.634

9.  The Disparate Approaches of General Practitioners to the Pharmaceuticalisation of Cardiovascular Disease Prevention.

Authors:  Tom Douglass; Michael Calnan
Journal:  Front Sociol       Date:  2021-05-21

10.  What is psychiatry? Co-producing complexity in mental health.

Authors:  Martyn Pickersgill
Journal:  Soc Theory Health       Date:  2012-07-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.